1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
SAMSUNG PHARMACEUTICAL.CO.,Ltd.

SAMSUNG PHARMACEUTICAL.CO.,Ltd.

KKRX:001360
1,271.00
KRW
-21.00
(-1.63%)
-1,394.67EPS
125.46BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3,261.49
1,280.62
1,273.39
1,189.13
867.19
818.49
689.12
713.15
746.52
697.01
699.02
490.34
490.87
454.08
Basic EPS, GAAP
-1,285.17
-1,004.11
-30.03
-544.68
-155.98
-36.55
106.46
-589.16
-547.66
-337.44
-333.83
-156
123
-1,457.31
Free Cash Flow per Basic Share
-102.47
-662.79
-658.7
-1,115.77
-25.54
-179.83
-263.24
-143.43
-152.68
-66.55
-544.05
-195.67
-243.06
-236.71
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1,244.37
786.06
1,292.7
1,713.68
1,871.87
2,041.33
2,185.94
1,788.33
1,710.78
1,379.03
1,042.9
1,124.68
1,286.07
767.75
Tangible Book Value per Share
1,220.21
777.41
1,039.37
1,626.67
1,828.61
1,991.26
2,180.65
1,778.08
1,699.07
1,362.89
967.02
1,065.11
1,117.17
598.85
Basic Weighted Avg Shares
14
24
33
40
48
57
65
68
74
74
74
90
94
94
Sales/Revenue/Turnover
46,921
30,288
42,165
47,194
41,919
46,484
44,566
48,269
54,901
51,832
51,955
44,294
46,074
42,736
Operating Margin (%)
-24.33
-65.44
-4.44
-13.41
-16.41
-10.29
-11.72
-20.3
-33.04
-26.94
-34.72
-33.48
-39.22
-37.8
Depreciation Expense
1,376
1,473
2,479
4,267
3,915
3,764
4,216
4,199
3,203
3,007
1,914
2,124
1,439
822
Net Income, GAAP
-18,489
-23,748
-994
-21,618
-7,540
-2,076
6,885
-39,877
-40,276
-25,093
-24,812
-14,092
11,545
-137,154
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
2.85
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-39.4
-78.41
-2.36
-45.81
-17.99
-4.47
15.45
-82.61
-73.36
-48.41
-47.76
-31.81
25.06
-320.93
Working Capital
3,664
-2,555
39,672
11,204
8,800
55,031
39,125
15,122
68,693
55,338
16,635
28,444
-3,329
-9,389
LT Debt
17,984
3,395
54,231
16,307
4,906
2,150
1,281
4,867
1,102
721
102
362
79
4,110
Total Equity
18,741
23,295
46,237
82,378
93,868
131,663
142,829
121,915
127,270
102,590
77,585
105,855
121,045
72,261
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-4.43
- -
- -
- -
- -
- -
-15.25
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
4.95
- -
- -
- -
- -
- -
10.2
- -
Return on Common Equity (%)
-69.18
-112.99
-2.86
-33.62
-8.56
-1.84
5.02
-30.12
-32.33
-21.83
-27.54
-15.36
10.18
-98.21

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
17,620
14,080
14,489
LT Borrowings
- -
4,000
4,000
LT Finance Leases
79
66
110
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
94
94
94
Market Capitalization
144,004
166,311
125,462

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
38,986
35,974
30,806
Cash, Cash Equivalents & STI
16,166
13,000
9,556
Accounts Receivable, Net
6,453
6,732
6,317
Inventories
10,247
11,592
10,324
Total Current Liabilities
42,315
37,320
40,195
Payables & Accruals
- -
- -
- -
ST Debt
17,620
14,080
14,489
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.76%
2.28%
14.35%
Free Cash Flow
140.63%
129.92%
29.07%
Net Income, GAAP
56.25%
-52.59%
-181.93%
Sales/Revenue/Turnover
1.35%
-0.47%
4.02%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,169
10,578
11,079
10,467
44,294
2025
11,357
10,898
12,002
11,817
46,074
2026
9,016
9,901
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-61
-119
195
-184.16
-156
2025
396
675
-320.55
-627.97
123
2026
93.15
-602
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Seong-Taek Jeong
Full Time Employees
87
Sector
Health technology
Industry
Pharmaceuticals: major
Address
35 Jeyakgongdan 2-gil Hwaseong-si GY South Korea 18622
IPO Date
Jul 4, 1975
Website
sspharm.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
SAMSUNG PHARM. Co., Ltd. engages in the development and distribution of a wide array of medicinal and health-related goods across South Korea. Its extensive pharmaceutical lineup includes specialized prescription drugs addressing various therapeutic areas such as pain relief, inflammation, weight management, cardiovascular health, and digestive system disorders. The company also supplies treatments for conditions like osteoporosis, respiratory issues, and infections, alongside muscle relaxants and essential vitamin formulations. Beyond prescribed medications, it provides numerous over-the-counter remedies for common ailments, nutritional supplements, revitalizing energy beverages, and functional foods designed for overall wellness. Established in 1929, the firm maintains its operational base in Hwaseong-si, South Korea.